State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Fujian Cancer Hospital, Fujian Provincial Cancer Hospital of Fujian Medical University, Fuzhou 350014, China.
Drug Discov Today. 2021 Oct;26(10):2282-2302. doi: 10.1016/j.drudis.2021.04.023. Epub 2021 Apr 22.
Globally, the incidence of thromboembolic diseases has increased in recent years, accompanied by an increase in patient mortality. Currently, several targeting delivery strategies have been developed to treat thromboembolic diseases. In this review, we discuss the mechanisms of thrombolysis and current anticoagulant drugs, particularly those with targeting capability, highlighting advances in the accurate treatment of thrombolysis with fewer adverse effects. Such approaches include magnetic drug-loading systems combined with molecular imaging to recanalize blood vessels and systems based on chimeric Arg-Gly-Asp (RGD) sequences that can target platelet glycoprotein receptor. With such progress in targeted antithrombotic drugs, targeted thrombolysis treatment shows significant potential benefit for patients.
近年来,全球范围内血栓栓塞性疾病的发病率有所增加,同时患者死亡率也有所上升。目前,已经开发出了几种靶向递药策略来治疗血栓栓塞性疾病。在这篇综述中,我们讨论了溶栓的机制和目前的抗凝药物,特别是那些具有靶向能力的药物,强调了通过更少的不良反应实现溶栓的精准治疗的进展。这些方法包括结合分子成像的磁性药物加载系统来再通血管,以及基于嵌合 Arg-Gly-Asp(RGD)序列的系统,这些系统可以靶向血小板糖蛋白受体。随着靶向抗血栓药物的这一进展,靶向溶栓治疗为患者带来了显著的潜在益处。